ATE413191T1 - Verwendung of interleukin-1 mutein als impfstoffadjuvans - Google Patents

Verwendung of interleukin-1 mutein als impfstoffadjuvans

Info

Publication number
ATE413191T1
ATE413191T1 AT00980942T AT00980942T ATE413191T1 AT E413191 T1 ATE413191 T1 AT E413191T1 AT 00980942 T AT00980942 T AT 00980942T AT 00980942 T AT00980942 T AT 00980942T AT E413191 T1 ATE413191 T1 AT E413191T1
Authority
AT
Austria
Prior art keywords
mutein
adjuvant
interleukin
animal
human
Prior art date
Application number
AT00980942T
Other languages
German (de)
English (en)
Inventor
Richard Dondero
Herman Staats
Original Assignee
Celltech Chiroscience Ltd
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Chiroscience Ltd, Univ Duke filed Critical Celltech Chiroscience Ltd
Application granted granted Critical
Publication of ATE413191T1 publication Critical patent/ATE413191T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT00980942T 1999-12-03 2000-12-04 Verwendung of interleukin-1 mutein als impfstoffadjuvans ATE413191T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16892899P 1999-12-03 1999-12-03

Publications (1)

Publication Number Publication Date
ATE413191T1 true ATE413191T1 (de) 2008-11-15

Family

ID=22613541

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00980942T ATE413191T1 (de) 1999-12-03 2000-12-04 Verwendung of interleukin-1 mutein als impfstoffadjuvans

Country Status (7)

Country Link
US (2) US6656462B2 (https=)
EP (1) EP1196193B1 (https=)
JP (1) JP2003515569A (https=)
AT (1) ATE413191T1 (https=)
AU (1) AU1813701A (https=)
DE (1) DE60040740D1 (https=)
WO (1) WO2001039803A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270758B1 (en) * 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
CN101267834B (zh) 2005-09-28 2013-06-05 赛托斯生物技术公司 白介素-1偶联物及其用途
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
EP2066347A1 (en) * 2006-09-28 2009-06-10 Cytos Biotechnology AG Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases
WO2009059328A2 (en) * 2007-11-02 2009-05-07 The Johns Hopkins University Multi- component l2 vaccine for prevention of human papillomavirus infection
EP2341929B1 (en) 2008-10-06 2017-01-25 University Of Chicago Compositions and methods related to bacterial emp proteins
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
US10080799B2 (en) 2010-02-12 2018-09-25 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
JP6002128B2 (ja) 2010-07-02 2016-10-05 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ プロテインＡ（ＳｐＡ）変種に関連する組成物および方法
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
AU2013252883B2 (en) 2012-04-26 2018-05-17 University Of Chicago Staphylococcal coagulase antigens and methods of their use
WO2014085767A1 (en) * 2012-11-29 2014-06-05 University Of Rochester Compositions and methods for treating immune conditions, including type1 diabetes
CN104740615A (zh) * 2013-12-31 2015-07-01 上海索菲里奥生物医药科技发展有限公司 IL-1β在制备用于治疗由金黄色葡萄球菌易感所引起的炎症的药物中的用途
TWI601742B (zh) * 2016-03-23 2017-10-11 國立清華大學 使宿主提早產生抗體及延長抗體保護時間的重組雞介白素１β蛋白質及其應用
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
WO2019183500A1 (en) 2018-03-23 2019-09-26 Hung Chiung Yu Coccidioides antigens and methods of their use
MX2021013833A (es) 2019-05-14 2022-03-17 Univ Chicago Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
EP4178609A4 (en) * 2020-07-07 2024-07-24 Orionis Biosciences, Inc. IMMUNOSTIMULATORY ADJUVANTS
EP4469079A1 (en) 2022-01-28 2024-12-04 Pfizer Inc. Coronavirus antigen variants
WO2025027492A1 (en) 2023-07-31 2025-02-06 Pfizer Inc. Coronavirus antigen variants

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342614A (en) * 1984-12-21 1994-08-30 Otsuka Pharmaceutical Co., Ltd. Method of treating arthritus or inflammation with IL-1β or derivatives thereof
US5503841A (en) 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
JP2591615B2 (ja) * 1986-03-14 1997-03-19 大塚製薬株式会社 インターロイキン−１β誘導体及び医薬
IT1217314B (it) 1987-02-20 1990-03-22 Sclavo Spa Nonapeptide sintetico ad attivita'adiuvante capace di potenziare in vivo la risposta anticorporale
EP0460052B1 (en) 1989-02-27 1998-04-15 New England Medical Center Il-1 biological activity inhibitors
DE69018990T2 (de) 1989-07-14 1995-12-14 Praxis Biolog Inc Stabile interleukine enthaltende impfstoffzusammensetzungen.
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines

Also Published As

Publication number Publication date
US20010036452A1 (en) 2001-11-01
WO2001039803A3 (en) 2002-02-21
AU1813701A (en) 2001-06-12
WO2001039803A2 (en) 2001-06-07
US20040253208A1 (en) 2004-12-16
EP1196193B1 (en) 2008-11-05
JP2003515569A (ja) 2003-05-07
EP1196193A2 (en) 2002-04-17
US6656462B2 (en) 2003-12-02
DE60040740D1 (de) 2008-12-18

Similar Documents

Publication Publication Date Title
ATE413191T1 (de) Verwendung of interleukin-1 mutein als impfstoffadjuvans
Comoy et al. The house dust mite allergen, Dermatophagoides pteronyssinus, promotes type 2 responses by modulating the balance between IL-4 and IFN-γ
Wynn et al. IL-12 enhances vaccine-induced immunity to schistosomes by augmenting both humoral and cell-mediated immune responses against the parasite
Mountford et al. Induction of Th1 cell-mediated protective immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant
Mahon et al. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells
DE69101753D1 (de) Lockvirus Impfstoff.
FI920132A0 (fi) Stabila vaccinkompositioner innehaollande interleukiner.
LU91324I2 (fr) Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)-gardasil/silgard
ATE229978T1 (de) Helicobacter proteine und impstoffe
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
Rotman et al. IL‐12 eliminates the Th‐2 dependent protective immune response of mice to larval Strongyloides stercoralis
NO20004972L (no) Derivater av pneumokokkale kolinbindende proteiner for vaksiner
ATE149202T1 (de) Gentechnologisch veränderte bakteriophagen und sie enthaltende impfstoffe
ATE422362T1 (de) Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose
WO2015138471A1 (en) Heat inactivated poxvirus improves vaccination results
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
Antúnez et al. Early IFN-γ production is related to the presence of interleukin (IL)-18 and the absence of IL-13 in experimental Trypanosoma cruzi infections
ATE515258T1 (de) Mukosales verabreichungssytem
ATE133074T1 (de) Verwendung von il-4 zur verstärkung der immunantwort auf infektiöse antigen- herausforderungen
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
WO1999022763A3 (en) Encapsulated immunomodulators useful as vaccine adjuvants
PT858345E (pt) Uso de muteinas de citocinas do tipo selvagem como imunogenios
Ahmed et al. Modulating Effects of Sensory and Autonomic Neuropeptides on Murine Splenocyte Proliferation and Cytokine Secretion Indd by Leishmania Major
Garcia et al. Protective immunity induced by a Trypanosoma cruzi soluble extract antigen in experimental Chagas' disease. Role of interferon γ

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties